靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2021-07-12 |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2020-10-24 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1997-12-09 |
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of AD-209
A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of AD-224
100 项与 Addpharma, Inc. 相关的临床结果
0 项与 Addpharma, Inc. 相关的专利(医药)
100 项与 Addpharma, Inc. 相关的药物交易
100 项与 Addpharma, Inc. 相关的转化医学